Table 4.
Drugs with a DF508CFTR corrector activity according to the literature
| Drug | Class | Use / MoA |
|---|---|---|
| Chloramphenicol (Carlile et al., 2007) | Antibiotics | Inhibits bacterial protein synthesis by preventing peptidyl transferase activity. |
| Chlorzoxazone (Carlile et al., 2007) | Muscle Relaxants | Inhibits degranulation of mast cells and prevents the release of histamine and slow-reacting substance of anaphylaxis. |
| Dexamethasone (Caohuy et al., 2009) | Glucocorticoid Agonists | Its anti-inflammatory properties are thought to involve phospholipase A2 inhibitory proteins, lipocortins. |
| Doxorubicin (Maitra et al., 2001) | Topoisomerase Inhibitors | DNA intercalator stabilizing the DNA-topoisomerase II complex. |
| Glafenine (Robert et al., 2010) | NSAID | Non-Steroidal Anti-Inflammatory. An anthranilic acid derivative with analgesic properties. |
| Liothyronine (Carlile et al., 2007) | Synthetic hormones | Increases the basal metabolic rate, affect protein synthesis and increase the body’s sensitivity to catecholamines. |
| Entinostat (Hutt et al., 2010) | HDAC Inhibitors | Inhibits preferentially HDAC 1, also HDAC 3. |
| Scriptaid (Hutt et al., 2010) | HDAC Inhibitors | Inhibits HDAC1, HDAC3 and HDAC8. |
| Strophanthidin (Carlile et al., 2007) | Cardiac Glycosides | Inhibits Na+/K+ ATPase. Also known to inhibit the interaction of MDM2 and MDMX. |
| Thapsigargin (Egan et al., 2002) | Calcium Channel Blockers | Inhibits non-competitively the sarco/endoplasmic Ca2+ ATPase. |
| Trichostatin-A (Hutt et al., 2010) | HDAC Inhibitors | Inhibits HDAC1, HDAC3, HDAC8 and HDAC7. |